Vitexin attenuates gastric precancerous lesions with EGFR as a potential target based on network pharmacology and molecular simulations

Submitted by Anonymous on

Precancerous gastric lesions (PLGC) represent a critical transitional stage toward gastric cancer, yet effective interventions to halt progression remain limited. Vitexin, a naturally occurring flavonoid, exhibits anti-cancer potential; however, its molecular targets and mechanisms in PLGC have not been fully...

Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions

Submitted by Anonymous on

The emergence of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) propelled EGFR-mutated patients of non-small cell lung cancer (NSCL 2 Acquired resistance mechanisms2.1 On-target resistance mechanisms Gefitinib and erlotinib, first-generation TKIs, are reversible inhibitors, and second-generation TKIs (represented by...

STAT3 signaling mediates EGFR-TKI resistance in non-small cell lung cancer by regulating stemness markers and telomerase, reversed by icaritin

Submitted by Anonymous on

Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) prolong the survival of patients with non-small cell lung cancer (NSCLC); however, drug resistance limits their long-term efficacy. The role of STAT3 signaling in EGFR-TKI resistance is not completely understood. Methods Using immunohistochemistry, we assessed...

Development of an EGFR-targeted adenoviral E4orf4 protein nanoparticle for cancer therapy

Submitted by Anonymous on

Abstract Early region 4 open reading frame 4 (E4orf4), a protein derived from human adenovirus, selectively induces non-canonical apoptosis in transformed cells by inhibiting multiple oncogenic signaling pathways. In this study, we designed an epidermal growth factor receptor (EGFR)-targeted E4orf4...

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy

Submitted by Anonymous on

Open AccessReview Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy by Daniel RosasDaniel Rosas SciProfiles Scilit Preprints.org Google Scholar 1,*, Jay DesaiJay Desai SciProfiles Scilit Preprints.org Google Scholar 2...

Young adults born moderately to extremely preterm have higher eGFR and cystatin C compared to young adults born at term

Submitted by Anonymous on

AbstractBackground Adolescents and adults born preterm are at increased risk for kidney dysfunction, possibly secondary to incomplete nephrogenesis. However, few long-term follow-up studies are available from U.S.-born preterm cohorts. Methods Using the Parkland Hospital Neonatal Intensive Care Unit Registry (Dallas,...

EGFR-Targeted Extracellular Vesicles Potentiate Doxorubicin-Induced Apoptosis and Tumor Suppression in Colorectal Cancer

Submitted by Anonymous on

Open AccessArticle EGFR-Targeted Extracellular Vesicles Potentiate Doxorubicin-Induced Apoptosis and Tumor Suppression in Colorectal Cancer by Chan Mi LeeChan Mi Lee SciProfiles Scilit Preprints.org Google Scholar 1,2, Ji Won ChoiJi Won Choi SciProfiles Scilit Preprints.org Google Scholar 1, Do Sang LeeDo...

Glabridin improves cardiac remodeling after myocardial infarction by activating PPARγ to regulate the ubiquitination and degradation of EGFR

Submitted by Anonymous on

AbstractBackground Acute myocardial infarction leads to myocardial inflammation and necroptosis, and is a major cause of heart failure, cardiovascular dysfunction, and mortality. Adverse remodeling and myocardial fibrosis following myocardial infarction are key pathophysiological processes contributing to poor prognosis. Licorice, a...

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Submitted by Anonymous on

Article content SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) - Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results...

Subscribe to Newsfeed